Each week we highlight five things affecting the life sciences industry. Here’s the latest.
Oura’s IPO filing underscores healthcare growth interest
- Oura’s initial public filing highlights its ambition to expand beyond consumer wellness, tracking into healthcare, leveraging partnerships with major healthcare and diagnostics companies, as well as healthcare providers, to make its wearable data more clinically useful.
- Per Endpoints News, while healthcare expansion could drive long-term growth, Oura disclosed that additional health-focused features may subject the company to greater U.S. Food and Drug Administration medical device regulation, potentially increasing compliance costs and regulatory risk.
AI organization expands biopharma strategy
- A major artificial intelligence organization is expanding its interest in the biopharma industry and is hiring a corporate development leader to pursue acquisitions, investments and partnerships with AI-focused life sciences companies.
- According to Endpoints News, the move builds on the organization’s recent biotech investments as it broadens its presence across areas such as drug development, lab automation, regulatory writing and healthcare data infrastructure.
UK pharma investment boost
- Global pharmaceutical companies have committed £1.98 billion in UK investment since September 2025 across 16 financial commitments from 13 companies, per the Association of the British Pharmaceutical Industry’s latest report, which credits the UK–U.S. trade deal’s tariff terms and higher cost-effectiveness thresholds instituted by the National Institute for Health and Care Excellence.
- Despite the investment boost, UK trial recruitment speed, medicine uptake and clawback rates remain uncompetitive versus other countries, with only 58% of trials open to recruitment within 60 days of approval, writes the Pharmaceutical Journal.
Venture capital firm raises $1.1 billion to support public biotechs
- A venture capital and investment firm raised over $1.1 billion for its biotech-focused public fund, bringing total capital raised for the strategy to $2.8 billion. The fund invests primarily in small- and mid-cap public biotech companies, with flexibility to participate in later-stage private company financings.
- According to Fierce Biotech, the raise reflects continued confidence in the biotech sector, supported by recent clinical, regulatory and commercial successes.
FDA names permanent CDER and CBER directors
- The FDA named Michael Davis and Karim Mikhail as permanent directors of the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), respectively.
- According to Biopharma Dive, analysts view the appointments as a sign of greater stability and continuity at the FDA, with expectations that the agency will maintain a more traditional and predictable regulatory approach.
For more insights in life sciences, check out RSM’s industry outlook.
